176 research outputs found

    Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy

    Get PDF
    Local tumor immune response and host immunity have been suggested as important prognosticators respectively in colorectal cancer. However, the utility of combination of these parameters remains inconclusive. The aim of this study was to investigate the combinational impact of local and host tumor immune response, as determined by tumor-infiltrating lymphocytes (TILs) and neutrophil-to-lymphocyte ratio (NLR), in patients with stage III colon cancer. Patients with stage III colon cancer homogeneously treated with surgery followed by FOLFOX chemotherapy between Jan 2007 and Aug 2013 were included retrospectively. Hematoxylin and eosin (H&E) stained tumor sections of local inflammatory infiltrate (TILs) were classified as 0-3 by the Klintrup-MΓ€kinen grading method. NLR was measured within 1 month of surgery. The association of NLR and TILs with survival, alone or combined, were measured using multivariate Cox proportional hazard regression analysis. Among 137 patients, 75 (54.7%) were identified as the high TIL group (TILs 2 and 3) and 97 (70.8%) as the low NLR group (NLR < 3). Of the patients with high TILs, 51 (68%) had a low NLR. In univariate analysis, operation time, complications, lymph node ratio (LNR), stage, TILs, and high TILs with low NLR were significantly associated with overall survival(OS). Multivariate Cox regression identified operation time, stage, and TILs as independent risk factors for OS. When high TILs with low NLR vs. others was entered into multivariate analysis, this also proved to be a significant predictor of OS (HR 4.1, 95% CI 1.1-14.2, P = 0.025), with an increased C-index and lower AIC value compared to TILs. Measuring TILs using H&E stained sections could stratify the prognosis of stage III colon cancer. Considering host immunity, using the combination of TILs and NLR, allowed the prognosis to be stratified in more detail.ope

    Robotic Surgery for Rectal Cancer and Cost-Effectiveness

    Get PDF
    Robotic surgery is considered as one of the advanced treatment modality of minimally invasive surgery for rectal cancer. Robotic rectal surgery has been performed for three decades and its application is gradually expanding along with technology development. It has several technical advantages which include magnified three-dimensional vision, better ergonomics, multiple articulated robotic instruments, and the opportunity to perform remote surgery. The technical benefits of robotic system can help to manipulate more meticulously during technical challenging procedures including total mesorectal excision in narrow pelvis, lateral pelvic node dissection, and intersphincteric resection. It is also reported that robotic rectal surgery have been shown more favorable postoperative functional outcomes. Despite its technical benefits, a majority of studies have been reported that there is rarely clinical or oncologic superiority of robotic surgery for rectal cancer compared to conventional laparoscopic surgery. In addition, robotic rectal surgery showed significantly higher costs than the standard method. Hence, the cost-effectiveness of robotic rectal surgery is still questionable. In order for robotic rectal surgery to further develop in the field of minimally invasive surgery, there should be an obvious cost-effective advantages over laparoscopic surgery, and it is crucial that large-scale prospective randomized trials are required. Positive competition of industries in correlation with technological development may gradually reduce the price of the robotic system, and it will be helpful to increase the cost-effectiveness of robotic rectal surgery.ope

    Changes in Body Composition During Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer

    Get PDF
    The impact of longitudinal anthropometric changes during adjuvant chemotherapy on long-term survival in non-metastatic colon cancer is unclear. Herein, we analyzed the prognostic significance of computed tomography (CT)-measured body composition changes in colon cancer patients who underwent surgery followed by adjuvant FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) chemotherapy. Data of 167 patients with stage III or high-risk stage II colon cancer were analyzed. Skeletal muscle index (SMI), skeletal muscle radiodensity (SMR), visceral fat index (VFI), subcutaneous fat index (SFI), and total fat index (TFI) changes during chemotherapy were calculated using preoperative and postchemotherapy CT image data. The Cox proportional hazard model was used to determine the correlation between changes in anthropometric values and overall survival (OS). The median changes (%) in SMI, SMR, VFI, SFI, and TFI over 210 days during chemotherapy were 8.7% (p < 0.001), 3.4% (p = 0.001), -19% (p < 0.001), -3.4% (p = 0.936), and -11.9% (p < 0.001), respectively. Cut-off values of changes in SMI (skeletal muscle index change, SMIC) and SMR (skeletal muscle radiodensity change, SMRC) were defined at -2% and -2 Hounsfield units (HU) respectively, whereas those of changes in VFI (visceral fat index change, VFIC), SFI (subcutaneous fat index change, SFIC), and TFI (total fat index change, TFIC) were based on values that provided the largest Ο‡2 on the Mantel-Cox test. Multivariable analysis revealed that low SMR measured on a postchemotherapy CT scan (hazard ratio, HR: 0.32, 95% confidence interval, CI: 0.15-0.70, p = 0.004) and visceral fat loss of at least 46.57% (HR: 0.31, 95% CI: 0.14-0.69, p = 0.004) were independent poor prognostic factors for OS. Severe visceral fat loss during FOLFOX chemotherapy and low skeletal muscle radiodensity measured on postchemotherapy CT scans are associated with poor OS in stage III and high-risk stage II colon cancer patients.ope

    Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer

    Get PDF
    BACKGROUND: This study aimed to evaluate the clinical outcomes of concurrent liver resection with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer patients with synchronous liver and peritoneal metastases. METHODS: Patients with colorectal liver and peritoneal metastasis who underwent complete cytoreduction and hyperthermic intraperitoneal chemotherapy with concurrent liver surgery between September 2014 and July 2018 were included. Perioperative outcomes, overall survival, and progression-free survival were analyzed retrospectively. RESULTS: In total, 22 patients were included. The median peritoneal cancer index was 13 (range, 0-26), and the median number of liver metastases was 3 (range, 1-13). The mean total operative time was 11.4 Β± 2.6 h. Minor postoperative complications (Clavien-Dindo grade I-II) were reported in 10 patients (45.5%), and major postoperative complications (grade III-V) were reported in five patients (22.7%), including one mortality patient. The median overall survival since diagnosis with metastasis was 27.4 months. The median overall survival since surgical intervention and the progression-free survival were 16.7 months and 7.1 months, respectively. CONCLUSIONS: This short-term follow-up study showed that, in an experienced center, combined resection with hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases was feasible and safe with acceptable oncologic outcomes.ope

    Eosinophilic encephalomyelitis in horses caused by protostrongylid parasites

    Get PDF
    Four thoroughbred horses showing lameness, ataxia, circling, depression, recumbency, and seizures, were examined. The horses had gross, pale- to dark-red manifestations and foci in the central nervous system (CNS). Multifocal to coalescing eosinophilic necrotizing encephalomyelitis was observed histologically in the CNS along with intact or degenerated nematodes. Nematodes had polymyarian-coelomyarian musculature, a smooth thin cuticle, and intestines lined by multinucleated cells with microvilli. These traits suggested the nematodes belonged to the family Protostrongylidae, which includes Parelaphostrongylus tenuis. It was concluded that the horses were infected by nematodes, presumably Parelaphostrongylus tenuis, resulting in eosinophilic necrotizing encephalomyelitis.ope

    Prediction of Metachronous Peritoneal Metastases After Radical Surgery for Colon Cancer: A Scoring System Obtained from an International Multicenter Cohort

    Get PDF
    Background: Since novel strategies for prevention and treatment of metachronous peritoneal metastases (mPM) are under study, it appears crucial to identify their risk factors. Our aim is to establish the incidence of mPM after surgery for colon cancer (CC) and to build a statistical model to predict the risk of recurrence. Patients and methods: Retrospective analysis of consecutive pT3-4 CC operated at five referral centers (2014-2018). Patients who developed mPM were compared with patients who were PM-free at follow-up. A scoring system was built on the basis of a logistic regression model. Results: Of the 1423 included patients, 74 (5.2%) developed mPM. Patients in the PM group presented higher preoperative carcinoembryonic antigen (CEA) [median (IQR): 4.5 (2.5-13.0) vs. 2.7 (1.5-5.9), P = 0.001] and CA 19-9 [median (IQR): 17.7 (12.0-37.0) vs. 10.8 (5.0-21.0), P = 0.001], advanced disease (pT4a 42.6% vs. 13.5%; pT4b 16.2% vs. 3.2%; P < 0.001), and negative pathological characteristics. Multivariate logistic regression identified CA 19-9, pT stage, pN stage, extent of lymphadenectomy, and lymphovascular invasion as significant predictors, and individual risk scores were calculated for each patient. The risk of recurrence increased remarkably with score values, and the model demonstrated a high negative predictive value (98.8%) and accuracy (83.9%) for scores below five. Conclusions: Besides confirming incidence and risk factors for mPM, our study developed a useful clinical tool for prediction of mPM risk. After external validation, this scoring system may guide personalized decision-making for patients with locally advanced CC.ope

    μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ˜ λ„μž… κ²°μ •μš”μΈ 뢄석

    Get PDF
    ν•™μœ„λ…Όλ¬Έ (석사)-- μ„œμšΈλŒ€ν•™κ΅ ν–‰μ •λŒ€ν•™μ› : μ •μ±…ν•™κ³Ό, 2014. 2. 김병섭.λ³Έ μ—°κ΅¬λŠ” μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ˜ λ„μž…μ— λ―ΈμΉ˜λŠ” κ²°μ •μš”μΈμ΄ λ―Όκ°„λΆ€λ¬Έκ³Ό 곡곡뢀문 간에 μ–΄λ– ν•œ 차이λ₯Ό κ°–κ³  λ‚˜νƒ€λ‚˜λŠ”μ§€λ₯Ό 비ꡐ λΆ„μ„ν•˜κ³ μž ν•˜μ˜€λ‹€. λ§Žμ€ 선행연ꡬ듀은 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ˜ λ„μž… κ²°μ •μš”μΈμ„ 뢄석함에 μžˆμ–΄μ„œ λ―Όκ°„/곡곡뢀문을 κ΅¬λΆ„ν•˜μ§€ μ•Šκ³  전체λ₯Ό λŒ€μƒμœΌλ‘œ λΆ„μ„ν•˜κ±°λ‚˜, λ―Όκ°„λΆ€λ¬Έ λ˜λŠ” κ³΅κ³΅λΆ€λ¬Έλ§Œμ„ λŒ€μƒμœΌλ‘œ λΆ„μ„ν•˜κ³  μžˆλ‹€. λ˜ν•œ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ™€ κ΄€λ ¨ν•˜μ—¬ 곡곡뢀문과 민간뢀문을 λΉ„κ΅ν•œ 연ꡬ듀은 λŒ€λΆ€λΆ„ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ˜ 운영 μ‹€νƒœλ₯Ό 뢄석함에 κ·ΈμΉ  뿐, κ·Έ λ„μž…κ³Όμ •μ— 영ν–₯을 λ―ΈμΉ˜λŠ” μš”μΈκΉŒμ§€ λΆ„μ„ν•˜μ§€λŠ” μ•Šκ³  μžˆλ‹€. 이와 λ”λΆˆμ–΄, μ—¬λŸ¬ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„λ“€μ˜ λ„μž… μ—¬λΆ€μ˜ 총합 건수λ₯Ό μ’…μ†λ³€μˆ˜λ‘œ ν•˜μ—¬ λΆ„μ„ν•˜κ±°λ‚˜ νŠΉμ • μ œλ„ ν•œ λ‘κ°œλ§Œμ„ λŒ€μƒμœΌλ‘œ λΆ„μ„ν•˜κ³  μžˆλŠ” 것이 μΌλ°˜μ μ΄λ‹€. λ”°λΌμ„œ λ³Έ μ—°κ΅¬λŠ” 곡곡뢀문과 λ―Όκ°„λΆ€λ¬Έ κ°„μ˜ 쑰직 차이에 따라 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ˜ λ„μž… μˆ˜μ€€κ³Ό κ²°μ •μš”μΈμ΄ 달라지며, κ°œλ³„ μ œλ„μ˜ νŠΉμ„±μ— λ”°λΌμ„œλ„ κ·Έ μ œλ„μ˜ λ„μž… 여뢀에 영ν–₯을 λ―ΈμΉ˜λŠ” μš”μΈμ΄ λ‹¬λΌμ§ˆ κ²ƒμ΄λΌλŠ” κ°€μ •μ—μ„œ μΆœλ°œν•˜μ˜€λ‹€. λ³Έ μ—°κ΅¬μ˜ μ’…μ†λ³€μˆ˜λŠ” μ—°λ΄‰μ œ, μ„±κ³Όλ°°λΆ„μ œ, λͺ©ν‘œκ΄€λ¦¬μ œ, λ‹€λ©΄ν‰κ°€μ œ, λ°œνƒμŠΉμ§„μ œ λ“± λŒ€ν‘œμ μΈ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ˜ λ„μž… μ—¬λΆ€λ₯Ό λ‚˜νƒ€λ‚΄λŠ” λ”λ―Έλ³€μˆ˜μ΄λ‹€. ν•œνŽΈ, μ œλ„ λ„μž…μ— 영ν–₯을 λ―ΈμΉ˜λŠ” κ²°μ •μš”μΈμ΄ 크게 합리성 관점과 μ •λ‹Ήμ„± κ΄€μ μœΌλ‘œ κ΅¬λΆ„λœλ‹€κ³  λ³΄λŠ” κΈ°μ‘΄ 선행연ꡬ듀을 따라, 합리성 κ΄€μ μ—μ„œ μ‹œμž₯κ²½μŸμˆ˜μ€€, μ°¨λ³„ν™”μ „λž΅ 채택여뢀λ₯Ό, μ •λ‹Ήμ„± κ΄€μ μ—μ„œ 곡곡뢀문 μ—¬λΆ€, 쑰직규λͺ¨, μΈμ‚¬λΆ€μ„œμ˜ 전문성을 λ…λ¦½λ³€μˆ˜λ‘œ μ±„νƒν•˜μ˜€λ‹€. λ§ˆμ§€λ§‰μœΌλ‘œ ν†΅μ œλ³€μˆ˜λŠ” 쑰직연령과 노동쑰합 유무둜 μ„€μ •ν•˜μ˜€λ‹€. λ³Έ μ—°κ΅¬μ—μ„œλŠ” 2009λ…„ μ‚¬μ—…μ²΄νŒ¨λ„λ°μ΄ν„°μ—μ„œ λ―Όκ°„λΆ€λ¬Έ 1,621개 κΈ°μ—…, 곡곡뢀문 116개 κΈ°μ—… 총 1,737개의 기업을 λŒ€μƒμœΌλ‘œ ν•˜μ—¬ λΆ„μ„ν•˜μ˜€λ‹€. 이듀을 λŒ€μƒμœΌλ‘œ, λ‹€μ€‘νšŒκ·€λΆ„μ„κ³Ό λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„μ„ μ‹€μ‹œν•˜μ˜€λ‹€. λ³Έ μ—°κ΅¬μ˜ μ£Όμš” κ²°κ³Όλ₯Ό μ •λ¦¬ν•˜λ©΄ λ‹€μŒκ³Ό κ°™λ‹€. 첫째, μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„λŠ” λŒ€λΆ€λΆ„ κ³΅κ³΅λΆ€λ¬Έμ—μ„œ λ„μž…μ΄ 더 μ κ·Ήμ μ΄λ‚˜, λͺ©ν‘œκ΄€λ¦¬μ œλ‚˜ λ°œνƒμŠΉμ§„μ œμ²˜λŸΌ κ°œλ³„ μ œλ„μ˜ νŠΉμ„±μ— 따라 λ―Όκ°„λΆ€λ¬Έκ³Ό 곡곡뢀문 간에 큰 차이가 μ—†λŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚˜κΈ°λ„ ν•œλ‹€. λ‘˜μ§Έ, 합리성 κ΄€μ λ³΄λ‹€λŠ” 쑰직규λͺ¨, μΈμ‚¬λΆ€μ„œμ˜ μ „λ¬Έμ„±κ³Ό 같은 μ •λ‹Ήμ„± κ΄€μ μ˜ μš”μΈλ“€μ΄ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž…μ— μœ μ˜ν•œ μ •(+)의 영ν–₯을 크게 미치며, 특히 κ³΅κ³΅λΆ€λ¬Έμ—μ„œ κ·ΈλŸ¬ν•œ κ²½ν–₯이 λ”μš± λ‘λ“œλŸ¬μ§€λŠ” κ²ƒμœΌλ‘œ ν™•μΈλ˜μ—ˆλ‹€. κ·ΈλŸ¬λ‚˜ 이 μ—­μ‹œ κ°œλ³„μ œλ„μ˜ νŠΉμ„±μ— 따라, 특히 λ―Όκ°„/곡곡의 쑰직문화 차이에 따라 영ν–₯μš”μΈμ΄ λ‹¬λΌμ§ˆ 수 μžˆλŠ” κ²ƒμœΌλ‘œ λ‚˜νƒ€λ‚¬λ‹€. 결둠적으둜, λ³Έ μ—°κ΅¬μ—μ„œλŠ” μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„λŠ” λ―Όκ°„/곡곡뢀문 κ°„ 쑰직정체성 및 λ‚΄μ™ΈλΆ€ ν™˜κ²½μ— μ˜ν•΄ λ„μž… 여뢀에 영ν–₯을 λ°›μœΌλ©°, μ΄λŠ” λ‹€μ–‘ν•œ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ— 따라 μ„œλ‘œ λ‹€λ₯΄κ²Œ λ‚˜νƒ€λ‚  수 μžˆλ‹€λŠ” 점을 λ°œκ²¬ν•  수 μžˆμ—ˆλ‹€. μ΄λŠ” ν–₯ν›„ λ―Όκ°„ λ˜λŠ” κ³΅κ³΅λΆ€λ¬Έμ˜ μ–΄λŠ 기업이 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„λ₯Ό λ„μž…, μš΄μ˜ν•˜λŠ” κ³Όμ •μ—μ„œ κ³ λ €ν•΄μ•Ό ν•  핡심 μš”μΈλ“€μ„ νŒŒμ•…ν•˜λŠ” 데 ν•˜λ‚˜μ˜ λ°©ν–₯성을 μ œμ‹œν•  수 μžˆμ„ 것이닀.λͺ© μ°¨ 제 1 μž₯ μ„œλ‘  7 제 1 절 연ꡬλͺ©μ  및 ν•„μš”μ„± 7 제 2 절 μ—°κ΅¬μ˜ λŒ€μƒκ³Ό 방법 10 제 2 μž₯ 이둠적 λ…Όμ˜μ™€ 선행연ꡬ κ²€ν†  12 제 1 절 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ— κ΄€ν•œ 이둠적 λ…Όμ˜ 12 1. μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ˜ κ°œλ… 및 κ΅¬μ„±μš”μ†Œ 12 2. κ³΅κ³΅κΈ°κ΄€μ˜ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ 19 제 2 절 μ œλ„ λ„μž… κ²°μ •μš”μΈμ— κ΄€ν•œ 이둠적 λ…Όμ˜ 24 1. 합리성 관점 24 2. μ •λ‹Ήμ„± 관점 25 제 3 절 선행연ꡬ κ²€ν†  28 제 3 μž₯ 연ꡬ섀계 및 뢄석방법 40 제 1 절 λ³€μˆ˜μ˜ μ‘°μž‘μ  μ •μ˜μ™€ κ°€μ„€μ„€μ • 40 1. μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž… κ²°μ •μš”μΈ (λ…λ¦½λ³€μˆ˜) 40 2. μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž… μ—¬λΆ€ (μ’…μ†λ³€μˆ˜) 48 3. ν†΅μ œλ³€μˆ˜ 48 제 2 절 μ—°κ΅¬μ˜ 뢄석틀 51 제 4 μž₯ 싀증 뢄석 53 제 1 절 κΈ°μˆ ν†΅κ³„ 뢄석 53 1. μ’…μ†λ³€μˆ˜ 53 2. λ…λ¦½λ³€μˆ˜ 55 3. ν†΅μ œλ³€μˆ˜ 59 제 2 절 상관뢄석 61 제 3 절 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ˜ λ„μž… κ²°μ •μš”μΈ 뢄석 64 1. μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž… μ§€μˆ˜μ˜ κ²°μ •μš”μΈ 뢄석 64 κ°€. OLS νšŒκ·€λͺ¨ν˜• κΈ°λ³Έκ°€μ •μ˜ 검증 64 λ‚˜. νšŒκ·€λΆ„μ„ κ²°κ³Ό 68 2. κ°œλ³„ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž…μ˜ κ²°μ •μš”μΈ 뢄석 74 κ°€. μ—°λ΄‰μ œ 75 λ‚˜. μ„±κ³Όλ°°λΆ„μ œ 78 λ‹€. λͺ©ν‘œκ΄€λ¦¬μ œ 81 라. λ‹€λ©΄ν‰κ°€μ œ 84 마. λ°œνƒμŠΉμ§„μ œ 87 제 4 절 μ†Œκ²° 91 제 5 μž₯ κ²°λ‘  98 제 1 절 μ—°κ΅¬κ²°κ³Όμ˜ μš”μ•½ 및 정책적 μ‹œμ‚¬μ  98 제 2 절 μ—°κ΅¬μ˜ ν•œκ³„ 및 ν–₯ν›„ μ—°κ΅¬κ³Όμ œ 103 μ°Έ κ³  λ¬Έ ν—Œ 105 Abstract 111 ν‘œ μ°¨λ‘€ ν‘œ 1 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„μ— λŒ€ν•œ λ‹€μ–‘ν•œ μ •μ˜λ“€ 15 ν‘œ 2 합리성 이둠과 μ •λ‹Ήμ„± 이둠의 비ꡐ 28 ν‘œ 3 선행연ꡬ μ œλ„ λ„μž… κ²°μ •μš”μΈ λΆ„λ₯˜ 32 ν‘œ 4 선행연ꡬ 뢄석결과 μ’…ν•© 34 ν‘œ 5 λ³€μˆ˜λͺ…κ³Ό λ³€μˆ˜μ˜ 츑정방법 50 ν‘œ 6 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž… ν˜„ν™© 53 ν‘œ 7 λ―Όκ°„β€€κ³΅κ³΅λΆ€λ¬Έμ˜ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž… ν˜„ν™© 54 ν‘œ 8 μ’…μ†λ³€μˆ˜ κΈ°μ΄ˆν†΅κ³„λŸ‰ 55 ν‘œ 9 μ‹œμž₯의 κ²½μŸμˆ˜μ€€κ³Ό μ°¨λ³„ν™”μ „λž΅ 채택 μ—¬λΆ€ ν˜„ν™© 56 ν‘œ 10 쑰직규λͺ¨μ— λ”°λ₯Έ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž… μ‹€νƒœ 57 ν‘œ 11 μΈμ‚¬λΆ€μ„œμ˜ μ „λ¬Έμ„± ν˜„ν™© 58 ν‘œ 12 λ…λ¦½λ³€μˆ˜ κΈ°μ΄ˆν†΅κ³„λŸ‰ 59 ν‘œ 13 쑰직연령 ν˜„ν™© 59 ν‘œ 14 노동쑰합 유무 ν˜„ν™© 60 ν‘œ 15 ν†΅μ œλ³€μˆ˜ κΈ°μ΄ˆν†΅κ³„λŸ‰ 60 ν‘œ 16 상관뢄석 κ²°κ³Ό 63 ν‘œ 17 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž…μ§€μˆ˜μ— λŒ€ν•œ νšŒκ·€λΆ„μ„ κ²°κ³Ό 70 ν‘œ 18 λ―Όκ°„β€€κ³΅κ³΅λΆ€λ¬Έμ˜ μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž…μ§€μˆ˜μ— λŒ€ν•œ νšŒκ·€λΆ„μ„ κ²°κ³Ό 72 ν‘œ 19 μ—°λ΄‰μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 76 ν‘œ 20 λ―Όκ°„λΆ€λ¬Έκ³Ό κ³΅κ³΅λΆ€λ¬Έμ˜ μ—°λ΄‰μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 77 ν‘œ 21 μ„±κ³Όλ°°λΆ„μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 80 ν‘œ 22 λ―Όκ°„λΆ€λ¬Έκ³Ό κ³΅κ³΅λΆ€λ¬Έμ˜ μ„±κ³Όλ°°λΆ„μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 81 ν‘œ 23 λͺ©ν‘œκ΄€λ¦¬μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 83 ν‘œ 24 λ―Όκ°„λΆ€λ¬Έκ³Ό κ³΅κ³΅λΆ€λ¬Έμ˜ λͺ©ν‘œκ΄€λ¦¬μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 84 ν‘œ 25 λ‹€λ©΄ν‰κ°€μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 86 ν‘œ 26 λ―Όκ°„λΆ€λ¬Έκ³Ό κ³΅κ³΅λΆ€λ¬Έμ˜ λ‹€λ©΄ν‰κ°€μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 87 ν‘œ 27 λ°œνƒμŠΉμ§„μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 89 ν‘œ 28 λ―Όκ°„λΆ€λ¬Έκ³Ό κ³΅κ³΅λΆ€λ¬Έμ˜ λ°œνƒμŠΉμ§„μ œ λ‘œμ§€μŠ€ν‹± νšŒκ·€λΆ„μ„ κ²°κ³Ό 90 ν‘œ 29 뢄석결과 μ’…ν•© 91 ν‘œ 30 λ―Όκ°„λΆ€λ¬Έκ³Ό 곡곡뢀문 κ°„ 뢄석결과 차이 94 ν‘œ 31 λ³Έ μ—°κ΅¬μ˜ κ°€μ„€ 채택 μ—¬λΆ€ 97 κ·Έλ¦Ό μ°¨λ‘€ κ·Έλ¦Ό 1 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž…μ§€μˆ˜μ˜ νšŒκ·€ μŠ€νŠœλ˜νŠΈν™” μž”μ°¨μ‚°μ λ„ 66 κ·Έλ¦Ό 2 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž… 건수의 νšŒκ·€ ν‘œμ€€ν™” μž”μ°¨ μ •κ·œ P-P λ„ν‘œ 67 κ·Έλ¦Ό 3 μ„±κ³Όμ£Όμ˜ μΈμ‚¬μ œλ„ λ„μž… 건수의 νšŒκ·€ ν‘œμ€€ν™” μž”μ°¨ νžˆμŠ€ν† κ·Έλž¨ 68Maste

    κ΅­ν† κ³„νšλ²•μƒ μ§€κ΅¬λ‹¨μœ„κ³„νšμ— κ΄€ν•œ 연ꡬ

    Get PDF
    ν•™μœ„λ…Όλ¬Έ (석사)-- μ„œμšΈλŒ€ν•™κ΅ λŒ€ν•™μ› : λ²•ν•™μ „λ¬ΈλŒ€ν•™μ› 법학과, 2018. 2. 김쒅보.μ§€κ΅¬λ‹¨μœ„κ³„νšμ΄λž€ 톡상 λ„λ‘œλ‘œ λ‘˜λŸ¬μ‹ΈμΈ ν•˜λ‚˜μ˜ 가ꡬ(著區)λ₯Ό λŒ€μƒμœΌλ‘œ μš©λ„μ§€μ—­μ œ λ„μ‹œκ³„νšμ΄ 담지 λͺ»ν•˜λŠ” μƒμ„Έν•œ λ‚΄μš©μ„ κ·œμœ¨ν•˜λŠ” λ„μ‹œκ³„νšμ„ λ§ν•œλ‹€. μ§€κ΅¬λ‹¨μœ„κ³„νšμ€ 2차원적이고 κ±°μ‹œμ μΈ μš©λ„μ§€μ—­μ œ λ„μ‹œκ³„νšκ³Ό μž…μ²΄μ μœΌλ‘œ κ°œλ³„ 건좕물을 κ·œμœ¨ν•˜λŠ” κ±΄μΆ•κ³„νšμ„ λ§€κ°œν•˜κΈ° μœ„ν•˜μ—¬ λ„μž…λ˜μ—ˆλ‹€. λ”°λΌμ„œ ν•„μ§€κ²½κ³„μ„ κΉŒμ§€ ν‘œν˜„λœ μ„Έλ°€ν•œ λ„λ©΄μ˜ ν˜•μ‹μ„ 띠며, 뢀속쑰항을 ν†΅ν•˜μ—¬ κ±΄μΆ•ν—ˆκ°€μš”κ±΄μ„ μž…μ²΄μ μœΌλ‘œ κ·œμœ¨ν•œλ‹€. λ˜ν•œ ν† μ§€μ΄μš©κ·œμ œλΏλ§Œ μ•„λ‹ˆλΌ κΈ°λ°˜μ‹œμ„€μ˜ μ§€μ •κΉŒμ§€ ν•¨κ»˜ κ·œμœ¨ν•˜λŠ” λ™μ‹œκ·œμ œλ°©μ‹μ„ μ·¨ν•œλ‹€. μ§€κ΅¬λ‹¨μœ„κ³„νšμ€ 이미 λ„μ‹œκ³„νšμ΄ μˆ˜λ¦½λ˜μ–΄ μžˆλŠ” κΈ°μ„±μ‹œκ°€μ§€λ₯Ό λŒ€μƒμœΌλ‘œ ν•˜λŠ” λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό λ„μ‹œκ³„νšμ‚¬μ—…κ³Ό μ—°κ³„ν•˜μ—¬ μˆ˜λ¦½λ˜λŠ” ν˜•μ„±μ  μ§€κ΅¬λ‹¨μœ„κ³„νš, 두 μœ ν˜•μœΌλ‘œ κ΅¬λΆ„λœλ‹€. κ΅­ν† κ³„νšλ²•μ€ κΈ°μ„±μ‹œκ°€μ§€ μ„ μž¬ν•˜λŠ” νšμ§€μ™€ κ±΄μΆ•ν—ˆμš©μ„±μ„ λ³€κ²½ν•  수 μžˆλŠ” 효λ ₯을 λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νšμ— λΆ€μ—¬ν•˜κ³  μžˆμ§€ μ•Šλ‹€. λ”°λΌμ„œ ν˜„μž¬ λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νšμ€ 지적곡뢀상 νšμ§€μ™€ κ±΄μΆ•ν—ˆμš©μ„±μ„ λ°˜μ˜ν•˜μ—¬ κ±΄μΆ•ν—ˆκ°€μš”κ±΄μ„ κ·œμœ¨ν•˜λŠ” 데 그치고 μžˆλ‹€. ν•œνŽΈ λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ κ²°μ •κ³Ό λ„μ‹œκ³„νšμ‹œμ„€μ‚¬μ—…μ˜ μ‹œν–‰μ„ 연계할 법적 μž₯μΉ˜κ°€ λ§ˆλ ¨λ˜μ–΄ μžˆμ§€ μ•Šμ•„ λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νšμœΌλ‘œ 미집행 λ„μ‹œκ³„νšμ‹œμ„€μ΄ λŒ€λŸ‰ μ–‘μ‚°λ˜κ³  μžˆλ‹€. ν˜•μ„±μ  μ§€κ΅¬λ‹¨μœ„κ³„νšμ€ κ·Έ λ‚΄μš©λŒ€λ‘œ λ„μ‹œν™˜κ²½μ΄ μ‘°μ„±λ˜λŠ” 효과λ₯Ό κ°€μ§€λ―€λ‘œ λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νšμ— λΉ„ν•˜μ—¬ μƒλŒ€μ μœΌλ‘œ κ°•λ ₯ν•œ λŒ€μ™Έμ  ꡬ속λ ₯을 κ°€μ§ˆ 수 μžˆλ‹€. κ·ΈλŸ¬λ‚˜ ν˜„ν–‰λ²•μ€ ν˜•μ„±μ  μ§€κ΅¬λ‹¨μœ„κ³„νšκ΅¬μ—­μ—μ„œ λ„μ‹œκ³„νšμš”μ†Œλ₯Ό λ³€κ²½ν•˜κ³ μž ν•˜λŠ” 경우 건좕법, 곡간정보관리법 등이 μ •ν•˜λŠ” μ ˆμ°¨μ— μ˜ν•˜λ„λ‘ ν•˜κ³  μžˆλ‹€. 이 μ ˆμ°¨μ—λŠ” λ„μ‹œκ³„νšμ  νŒλ‹¨μ΄ κ°œμž…λ  여지가 μ—†λ‹€. μ§€κ΅¬λ‹¨μœ„κ³„νšμ€ ν•„μ§€λ‹¨μœ„μ˜ κ·œμœ¨μ„ ν•˜κ³  ν† μ§€μ΄μš©κ·œμ œμ™€ κΈ°λ°˜μ‹œμ„€μ˜ μ‘°ν™”λ₯Ό 도λͺ¨ν•˜λŠ” λ„μ‹œκ³„νšμ΄λ‹€. λ”°λΌμ„œ ν˜„ν–‰ λ„μ‹œκ³„νšμœΌλ‘œλŠ” μœ μΌν•˜κ²Œ νšμ§€, κ±΄μΆ•ν—ˆμš©μ„±, κΈ°λ°˜μ‹œμ„€ λ“± λͺ¨λ“  λ„μ‹œκ³„νšμš”μ†Œμ— κ΄€ν•œ 사항을 κ·œμœ¨ν•  수 μžˆλŠ” 잠재λ ₯을 가지고 μžˆλ‹€. κ·ΈλŸ¬λ‚˜ κ΅­ν† κ³„νšλ²•μ€ μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ μ΄λŸ¬ν•œ 잠재λ ₯을 μΆ©λΆ„νžˆ 살리지 λͺ»ν•˜κ³  μžˆλ‹€.제 1 μž₯ μ„œλ‘  1 제 1 절 μ—°κ΅¬μ˜ λͺ©μ  1 제 2 절 μ—°κ΅¬μ˜ 방법과 λ²”μœ„ 3 제 2 μž₯ λ„μ‹œκ³„νšμ˜ μ˜μ˜μ™€ μœ ν˜• 5 제 1 절 λ„μ‹œκ³„νšμ˜ 의의 5 β… . 건좕학과 λ„μ‹œκ³΅ν•™ λΆ„μ•Όμ—μ„œ λ„μ‹œκ³„νšμ˜ 의의 5 1. λ„μ‹œκ³„νš κ°œλ… μ •λ¦½μ˜ ν•„μš”μ„± 5 2. λ„μ‹œκ³„νš κ΄€λ ¨ κ°œλ…μ˜ λ°œλ‹¬ μ—°ν˜ 6 3. λ„μ‹œκ³„νš 방법둠 8 β…‘. λ„μ‹œκ³„νšμ— λŒ€ν•œ 법학적 해석 10 1. λ„μ‹œκ³„νšμ— λŒ€ν•œ 법학적 ν•΄μ„μ˜ ν•„μš”μ„± 10 2. λ„μ‹œκ³„νšμ˜ 법적 κ°œλ… 11 (1) ν–‰μ •κ³„νšμœΌλ‘œμ„œ λ„μ‹œκ³„νš 11 (2) ν–‰μ •κ³„νšκ³Ό κ³„νšμž¬λŸ‰ 12 (3) ν–‰μ •κ³„νšμ˜ λΆ„λ₯˜ 12 κ°€. μ’…ν•©κ³„νšκ³Ό λΆ€λ¬Έλ³„κ³„νš 13 λ‚˜. μƒμœ„κ³„νšκ³Ό ν•˜μœ„κ³„νš 13 λ‹€. ꡬ속적 κ³„νšκ³Ό 비ꡬ속적 κ³„νš 13 (4) λ„μ‹œκ³„νšκ³Ό μž¬μ‚°κΆŒ μ œν•œ 14 3. λ„μ‹œκ³„νšμ˜ 법적 κΈ°λŠ₯ 15 4. λ„μ‹œκ³„νšμ˜ 법적 μ„±μ§ˆ 15 (1) λ„μ‹œκ³„νšμ˜ μ²˜λΆ„μ„± 15 (2) κ³„νšλ³΄μž₯청ꡬꢌ과 κ³„νšλ³€κ²½μ²­κ΅¬κΆŒ 16 제 2 절 λ„μ‹œκ³„νšμ˜ μœ ν˜• 19 β… . 적극적 κ³„νšκ³Ό μ†Œκ·Ήμ  κ³„νš 19 β…‘. μ§€κ΅¬λ‹¨μœ„λ°©μ‹κ³Ό λ„μ‹œλ‹¨μœ„λ°©μ‹ 19 β…’. λ™μ‹œκ·œμ œλ°©μ‹κ³Ό λΆ„λ¦¬κ·œμ œλ°©μ‹ 20 제 3 절 κ΅­ν† κ³„νšλ²•μƒ λ„μ‹œκ³„νšμ˜ 체계 22 β… . μš°λ¦¬λ‚˜λΌ λ„μ‹œκ³„νš μ œλ„μ˜ λ³€μ²œ 22 1. λ„μ‹œκ³„νš μ œλ„μ˜ λ„μž…κ³Ό λ°œλ‹¬ 22 2. κ΅­ν† κ³„νšλ²•μƒ λ„μ‹œκ³„νš μ œλ„ 23 β…‘. λ„μ‹œκΈ°λ³Έκ³„νšκ³Ό λ„μ‹œκ³„νš 24 1. ν˜„ν–‰ κ΅­ν† κ³„νšλ²•μƒ μš©μ–΄μ˜ 이해 24 2. λ„μ‹œκΈ°λ³Έκ³„νšκ³Ό λ„μ‹œκ³„νšμ˜ 관계 25 β…’. λ„μ‹œκ³„νšμ˜ μ’…λ₯˜ 26 1. μ„œμ„€ 26 2. μš©λ„μ§€μ—­μ œ λ„μ‹œκ³„νš 26 (1) 의의 26 (2) μš©λ„μ§€κ΅¬Β·κ΅¬μ—­μ œ 27 3. λ„μ‹œκ³„νšμ‹œμ„€κ³„νš 28 4. κ°œλ°œμ œν•œμ œ λ„μ‹œκ³„νš 28 5. μ§€κ΅¬λ‹¨μœ„κ³„νš 29 제 3 μž₯ μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ κ°œλ…κ³Ό 수립절차 30 제 1 절 μ„œμ„€ 30 제 2 절 μ§€κ΅¬λ‹¨μœ„κ³„νš μ œλ„ λ„μž… μ΄μ „μ˜ μ œλ„ 31 β… . 건좕법상 λ„μ‹œμ„€κ³„ μ œλ„ 31 1. λ„μ‹œμ„€κ³„ μ œλ„μ˜ λ„μž…κ³Ό 의의 31 2. λ„μ‹œμ„€κ³„ μ œλ„μ˜ 문제점 32 3. λ„μ‹œμ„€κ³„ μ œλ„μ˜ κ°œμ„  33 β…‘. λ„μ‹œκ³„νšλ²•μƒ μƒμ„Έκ³„νšκ΅¬μ—­ μ œλ„ 34 1. μƒμ„Έκ³„νšκ΅¬μ—­ μ œλ„μ˜ λ„μž…κ³Ό 의의 34 2. μƒμ„Έκ³„νšκ΅¬μ—­ μ œλ„μ™€ λ„μ‹œμ„€κ³„ μ œλ„μ˜ 비ꡐ 35 3. μƒμ„Έκ³„νšκ΅¬μ—­ μ œλ„μ˜ 문제점 36 제 3 절 μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ 의의 38 β… . μ§€κ΅¬λ‹¨μœ„κ³„νš μ œλ„μ˜ λ„μž… 38 β…‘. μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ νŠΉμ§• 38 1. μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ ν˜•μ‹ 38 2. μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ λŒ€μƒ 지역 39 (1) μ§€κ΅¬λ‹¨μœ„κ³„νšκ΅¬μ—­μ˜ 의의 39 (2) κ΅­ν† κ³„νšλ²•μƒ μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ λŒ€μƒ 지역 40 3. μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ 법적 μ§€μœ„ 41 β…’. μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ λ‚΄μš© 42 1. κ°œκ΄€ 42 2. ν† μ§€μ΄μš©κ·œμ œ 43 3. κΈ°λ°˜μ‹œμ„€μ˜ 지정 44 제 4 절 μ§€κ΅¬λ‹¨μœ„κ³„νšμ— νŠΉμˆ˜ν•œ 수립절차 45 β… . μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ μž…μ•ˆ 45 β…‘. μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ κ²°μ • 45 제 5 절 μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό λ‹€λ₯Έ λ„μ‹œκ³„νšμ˜ 관계 47 β… . μš©λ„μ§€μ—­μ œ λ„μ‹œκ³„νšκ³Όμ˜ 관계 47 β…‘. λ„μ‹œκ³„νšμ‹œμ„€κ³„νšκ³Όμ˜ 관계 48 β…’. λ„μ‹œκ³„νšμ‚¬μ—…κ³„νšκ³Όμ˜ 관계 49 1. λ„μ‹œκ³„νšμ‚¬μ—…μ˜ κ°œλ… 49 2. λ„μ‹œκ³„νšμ‚¬μ—…κ³„νšμ˜ 의의 49 (1) ν† μ§€μ΄μš©κ³„νšμ˜ 의의 49 (2) λ„μ‹œκ³„νšμ‚¬μ—…κ³„νšμ˜ 수립 51 3. λ„μ‹œκ³„νšμ‚¬μ—…κ³„νšκ³Ό μ§€κ΅¬λ‹¨μœ„κ³„νš 51 제 4 μž₯ μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ μœ ν˜•κ³Ό 법적 효과 54 제 1 절 μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ μœ ν˜• 54 β… . μ„œμ„€ 54 β…‘. λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νš 55 β…’. ν˜•μ„±μ  μ§€κ΅¬λ‹¨μœ„κ³„νš 55 제 2 절 μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό νšμ§€ 57 β… . 필지λ₯Ό κ΅¬νšν•˜λŠ” νšμ§€ 57 β…‘. ν•„μ§€μ˜ κ°œλ… 57 β…’. νšμ§€μ™€ λ„μ‹œκ³„νš 58 1. λ„μ‹œκ³„νšμ—μ„œ νšμ§€κ°€ κ°€μ§€λŠ” 의미 58 2. ν•„μ§€μ˜ λΆ„ν• κ³Ό 병합 58 3. νšμ§€μ™€ μ§€κ΅¬λ‹¨μœ„κ³„νš 59 β…£. λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό νšμ§€ 59 β…€. ν˜•μ„±μ  μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό νšμ§€ 61 제 3 절 μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό κ±΄μΆ•ν—ˆμš©μ„± 62 β… . κ±΄μΆ•ν—ˆμš©μ„±μ˜ 의의 62 β…‘. κ±΄μΆ•ν—ˆμš©μ„±κ³Ό 지λͺ©μΈ λŒ€(垈) 62 1. 지λͺ©μ˜ 의의 62 2. λŒ€(垈)의 특ꢌ적 μ§€μœ„ 63 β…’. κ±΄μΆ•ν—ˆμš©μ„±μ„ λΆ€μ—¬ν•˜λŠ” λ„μ‹œκ³„νš 64 1. λ„μ‹œκ³„νšμ‚¬μ—…κ³„νš 64 2. ν† μ§€μ˜ ν˜•μ§ˆ λ³€κ²½ 64 (1) ν† μ§€ν˜•μ§ˆλ³€κ²½μ˜ 의의 65 (2) ν† μ§€ν˜•μ§ˆλ³€κ²½μ˜ ν—ˆκ°€μš”κ±΄κ³Ό 절차 65 β…£. λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό κ±΄μΆ•ν—ˆμš©μ„± 66 β…€. ν˜•μ„±μ  μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό κ±΄μΆ•ν—ˆμš©μ„± 67 제 4 절 μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό κ±΄μΆ•ν—ˆκ°€μš”κ±΄ 68 β… . λ„μ‹œκ³„νšμ— μ˜ν•œ κ±΄μΆ•ν—ˆκ°€μš”κ±΄ 68 β…‘. μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ κ±΄μΆ•ν—ˆκ°€μš”κ±΄ 규율 방식 69 제 5 절 μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό κΈ°λ°˜μ‹œμ„€ 71 β… . κΈ°λ°˜μ‹œμ„€ 일반 71 1. κΈ°λ°˜μ‹œμ„€μ˜ 의의 71 2. λ„μ‹œκ³„νšμ‹œμ„€μ˜ μ„€μΉ˜ 절차 71 (1) λ„μ‹œκ³„νšμ‹œμ„€μ˜ κ²°μ • 71 (2) λ„μ‹œκ³„νšμ‹œμ„€μ‚¬μ—…μ˜ μ‹œν–‰ 72 β…‘. λ„μ‹œκ³„νšμ‹œμ„€κ³Ό μž¬μ‚°κΆŒ μ œν•œ 73 1. λ„μ‹œκ³„νšμ‹œμ„€μ˜ κ²°μ •κ³Ό κ±΄μΆ•ν–‰μœ„ μ œν•œ 73 2. μ‹€μ‹œκ³„νšμ˜ 인가와 수용ꢌ 73 3. μž₯기미집행 λ„μ‹œκ³„νšμ‹œμ„€ 74 β…’. κΈ°λ°˜μ‹œμ„€μ˜ λ°°μΉ˜μ™€ 규λͺ¨λ₯Ό μ •ν•˜λŠ” μ§€κ΅¬λ‹¨μœ„κ³„νš 76 β…£. λ³€ν˜•μ  μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό κΈ°λ°˜μ‹œμ„€ 76 β…€. ν˜•μ„±μ  μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό κΈ°λ°˜μ‹œμ„€ 77 제 5 μž₯ ν˜„ν–‰ μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ ν•œκ³„ 78 제 1 절 ν˜„ν–‰ μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ 문제점 78 β… . μ„œμ„€ 78 β…‘. 성격이 λ‹€λ₯Έ 두 μ§€κ΅¬λ‹¨μœ„κ³„νš 78 β…’. νšμ§€κ³„νšμ˜ λΆ€μž¬ 79 β…£. κ±΄μΆ•ν—ˆμš©μ„± 규제의 λΆ€μž¬ 80 β…€. μž₯기미집행 λ„μ‹œκ³„νšμ‹œμ„€μ˜ μ–‘μ‚° 81 제 2 절 μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ κΈ°λŠ₯ 82 β… . μ§€κ΅¬λ‹¨μœ„κ³„νšκ³Ό λ…μΌμ˜ B-plan 82 β…‘. μ§€κ΅¬λ‹¨μœ„κ³„νšμ˜ νŠΉμˆ˜μ„± 82 제 6 μž₯ κ²°λ‘  84 μ°Έκ³ λ¬Έν—Œ 86 Abstract 89Maste
    • …
    corecore